NCT05535855View on ClinicalTrials.gov

UCD19 CAR T Therapy in Adults With B-ALL and MRD Positivity in CR1

PHASE1RecruitingINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

January 24, 2024

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2030

Conditions
Acute Lymphoid LeukemiaAcute Lymphoblastic Leukemia
Interventions
DRUG

CD19 Directed CAR T Cell

The UCD19 CAR T cells are developed through transfection of autologous peripheral blood mononuclear cells with a lentivirus carrying the DNA that encodes a short chain fragment variable region (scFv) derived from an anti-CD19 monoclonal antibody, among other elements.

Trial Locations (1)

80045

RECRUITING

University of Colorado Hospital, Aurora

All Listed Sponsors
lead

University of Colorado, Denver

OTHER